FIGURE 2 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

<p>IHC analysis of paired screening and on-treatment (week 5–6) tumor biopsies, from patients receiving itacitinib or parsaclisib in combination with pembrolizumab. <b>A,</b> Study Part 1 (T-cell infiltration in combined tumor plus intratumoral stromal regions: CD3⁺, CD8⁺, FoxP3⁺ cells/mm²): itacitinib (Group A-1 and A-2, 300 mg once daily) plus pembrolizumab 200 mg every 3 weeks (upper, <i>n</i> = 9); parsaclisib (Group B, 0.3–1 mg once daily, or 2.5 mg every other day; B-1 and B-2, 20–30 mg once daily) plus pembrolizumab 200 mg every 3 weeks (lower, <i>n</i> = 11). <b>B,</b> Study Part 1 (CD8⁺:FoxP3⁺ ratio in combined tumor plus intratumoral stromal regions): itacitinib (300 mg) plus pembrolizumab (left, <i>n</i> = 9); parsaclisib (Group B, 0.3–1 mg once daily, or 2.5 mg every other day; B-1 and B-2, 20–30 mg once daily) plus pembrolizumab 200 mg every 3 weeks (right, <i>n</i> = 11). <b>C,</b> Study Part 2 (T-cell infiltration: CD3⁺, CD8⁺, FoxP3⁺ cells/mm²): parsaclisib 0.3 mg once daily plus pembrolizumab (<i>n</i> = 8 pairs; NSCLC = 1, SCLC = 4, UC = 3). <b>D,</b> Study Part 2 (CD8⁺:FoxP3⁺ ratio): parsaclisib 0.3 mg once daily plus pembrolizumab 200 mg every 3 weeks (<i>n</i> = 8 pairs; NSCLC = 1, SCLC = 4, UC = 3). NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer; UC, urothelial carcinoma.</p>

Duke Scholars

Author Niharika Bansal Mettu Medicine, Medical Oncology